|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol and Palmitoylethanolamide for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet
The purpose of the study is to evaluate whether the DIA/NPR-6 is a better pain reliever in patients with diabetic neuropathic pain of the feet compared to placebo.
100 Clinical Results associated with Pure Green Pharmaceuticals, Inc.
0 Patents (Medical) associated with Pure Green Pharmaceuticals, Inc.
100 Deals associated with Pure Green Pharmaceuticals, Inc.
100 Translational Medicine associated with Pure Green Pharmaceuticals, Inc.